Bloomberg Business

Eisai and Biogen’s Alzheimer’s Drug Moves Closer to Full US Approval

Eisai Co. and Biogen Inc. moved closer to full US approval for their Alzheimer’s drug Leqembi after the Food and Drug Administration posted documents indicating it sees no barriers to clearance, setting the product up for likely government health-plan coverage.

Trump Gets Target Letter In Special Counsel Documents Probe

Donald Trump’s legal team has been notified by the Justice Department that the former US president is a target in a federal investigation into the handling of classified documents, according to a person familiar with the matter.

Close Bitnami banner
Bitnami